
Antje Hjerpe was nominated as an MPN Hero for her long-term dedication, stewardship and volunteer service to the organization.

Antje Hjerpe was nominated as an MPN Hero for her long-term dedication, stewardship and volunteer service to the organization.

New York artist and GIST survivor, Ellen Mayer, painted "Balancing Act" to describe how she felt about her cancer experience. The artwork was later selected as one of 10 pieces to be publicly painted for The Hope Murals Project.

Susan Hope Schaffer, the 2014 Oncology on Canvas overall winner, shares how her experience with breast cancer helped her evolve as an artist.

For the 10th anniversary of the Oncology on Canvas art competition, Lilly Oncology and the National Coalition for Cancer Survivorship created The Hope Murals Project, a traveling exhibit throughout the U.S.

Patrick Borgen, MD, talks about advances in breast cancer surgery, faster clinical trials, and better genomic profiling.

Breast cancer is a complicated family of diseases – the goal is personalized medicine, and a team-based approach should be the standard of care.

Several studies announcing the latest research in different cancers, including prostate, breast and lung cancers, were presented at the 2014 European Society of Medical Oncology's annual meeting in Madrid, Spain.

Patrick Borgen, MD, discusses the benefits of early detection versus overtreatment of breast cancer associated with routine breast cancer screening.

Patrick Borgen, MD, shares his thoughts on the ethics and the efficacy of undergoing pre-emptive double mastectomy in women who have a BRCA mutation, which can greatly increase their risk for breast and ovarian cancers.

Experts review an innovative study, called the ATEMPT study, which looks at adjuvant T-DM1 in women with HER2-positive breast cancer.

Debu Tripathy, MD, editor-in-chief of CURE magazine, shares the latest research in metastatic breast cancer, including targeted drugs being tested in early-phase studies that appear promising, including the PARP inhibitor veliparib, the CDK4/6 inhibitor palbociclib and the anti-angiogenesis drug trametinib.